We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

We recently published a list of Jim Cramer is Talking About These 10 Stocks. In this article, we are going to take a look at ...

Johnson & Johnson’s biggest strength is its ... Meanwhile, J&J has one of the largest R&D budgets among pharma companies. JNJ is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and ...

JNJ boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Johnson & Johnson are trading at a forward earnings multiple of 14.5X, as well as a PEG Ratio ...